CTOs on the Move

Celgene

www.celgene.com

 
Celgene Corporation is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Our talent, scientific knowledge and research capabilities help us to deliver access to innovative, disease-altering therapies to those who need them most. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies. Celgene is headquartered in Summit, New Jersey, and employs more than 7,000 people located in more than 60 countries.
  • Number of Employees: >100K
  • Annual Revenue: > $1 Billion
  • www.celgene.com
  • 86 Morris Avenue
    Summit, NJ USA 07901
  • Phone: 908.673.9000

Executives

Name Title Contact Details
Peter Fourie
Executive Director, Information Technology Planning and Operations Profile
Eric Galis
Vice President of Information Security Profile
Maritza Osorio
Director of Information Technology Business Partner Profile
April Reeve
Director of Enterprise Information Strategy and Architecture Profile

Similar Companies

GangaGen Inc

GangaGen Inc is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chiropractors Buying Group

Chiropractors Buying Group is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Epredia

Improving lives by enhancing precision cancer diagnostics.

Strateos

Strateos is a pioneer in the development of remote access laboratories and lab control software for life science discovery.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.